R&D Spin-outs in the pharmaceutical industry
The high number of research and development (R&D) spin-outs in the pharmaceutical industry during the last 10 years focusing on drug development or offering specialised services demonstrates that pharmaceutical companies believe, through doing this, they can improve R&D performance....
Verfasser: | |
---|---|
FB/Einrichtung: | FB 12: Chemie und Pharmazie |
Dokumenttypen: | Artikel |
Medientypen: | Text |
Erscheinungsdatum: | 2011 |
Publikation in MIAMI: | 05.08.2012 |
Datum der letzten Änderung: | 18.03.2016 |
Quelle: | Journal of Business Chemistry, 8 (2011) 3, S. 101-113 |
Angaben zur Ausgabe: | [Electronic ed.] |
Fachgebiet (DDC): | 330: Wirtschaft |
Lizenz: | InC 1.0 |
Sprache: | English |
Anmerkungen: | Section "Research Paper" |
Format: | PDF-Dokument |
URN: | urn:nbn:de:hbz:6-79379590027 |
Permalink: | https://nbn-resolving.de/urn:nbn:de:hbz:6-79379590027 |
Onlinezugriff: | 2011_vol-8_iss3_101-113.pdf |
The high number of research and development (R&D) spin-outs in the pharmaceutical industry during the last 10 years focusing on drug development or offering specialised services demonstrates that pharmaceutical companies believe, through doing this, they can improve R&D performance. In a study, 43 European drug development as well as service oriented R&D spin-outs were analysed with regard to background, impact, realisation and the underlying strategy of the pharmaceutical parent companies. Spin-out creation can help to refocus the company strategy. Following a merger or simply complementing a strategic realignment on core areas, spin-outs provide a valuable option to leverage assets of low strategic importance, or under-exploited assets in their parent companies. Key aspects are strengthening the entrepreneurial spirit, a clear focus on core activities, performance-oriented controlling through cash-driven key indicators, high identification with the company, and appropriate financial incentives for management and staff.